BREAKING UPDATE: Today, the U.S. Supreme Court granted a stay of an order issued by the Fifth Circuit Court of Appeals in Louisiana v. FDA. The FDA’s current rules, which allow people to receive mifepristone by mail or pharmacy, are now in place as the case proceeds on the merits.
UCLA Law Center on Repro Health, Law, & Policy
We just filed an amicus brief in the Supreme Court on behalf of 360 repro health researchers explaining why dispensing mifepristone by mail and at pharmacies is safe and backed by science!
The analysis led by Graduate Researcher Monika Nayak, Research Analyst Leslie Serrano and Research Director Subasri Narasimhan found that participants got an average of $920 per month in direct cash support, helping families manage the strain associated with pregnancy, childbirth, and postpartum.
